Le Lézard
Classified in: Health, Covid-19 virus
Subject: MRR

Ibuprofen API Market is Projected to Reach US$ 772.2 Mn by the end of 2029: Future Market Insights, Inc.


Leading market participants of the Ibuprofen API Market elaborated in the report include BASF SE, BIOCAUSE Inc., IOL Chemicals And Pharmaceuticals Limited, SI Group, Inc., Sino-US Zibo Xinhua-Perrigo Pharmaceutical Co., Ltd., Solara Active Pharma Sciences Limited, Granules India Limited

NEWARK, Del., May 16, 2022 /PRNewswire/ -- The global Ibuprofen API Market surpassed US$ 626.2 Mn in 2022 and is anticipated to increase at a CAGR of 3% to reach US$ 772.2 Mn by 2029. as per the findings of a new Future Market Insights (FMI) study. The primary factors for the growth of the Ibuprofen API market include continuous demand for low-cost non-steroidal anti-inflammatory drugs (NSAID) and the scale and age of manufacturing facilities.

FMI_Logo

Increasing API drug shortages and assembling a task force to overcome these problems, the emergence of cost-effective drug manufacturers in various countries and the supply of API drugs, primarily in developing countries, are further driving ibuprofen API market growth.

The pharmaceutical API industry is witnessing a substantial crunch in supply and demand of Ibuprofen API, halted production from major ibuprofen API manufacturers, and supply chain disruption in China further led by declining sales in India.

Request For Report Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-11260

The volatility in Ibuprofen API is due to factors such as a lower number of competitors, reduced utilization ratio, lower margin level, new higher-value opportunities in complex combinations and high-grade API, the pace of facility inspection by FDA, and ramping up production capacity of through mergers and consolidation.

The diverse range of diseases, primarily cardiovascular disease, infectious diseases, diabetes, and kidney-related complications, has a high prevalence, globally. Thus, the increasing prevalence of a diverse range of diseases among all age groups and its burden, globally, drives the demand for drug development and its market.

There has been an upsurge in the usage of advanced technologies, such as high throughput, bioinformatics and combinatorial chemistry for better drug candidate identification. Drug discovery has evolved significantly with emerging technologies, helping the process to become more refined, accurate, and less time-consuming. Due to automation, multi-detector readers, imaging hardware and software, high-throughput screening is one of the most widely used drug discovery technologies.

Leading Companies Profiled in Ibuprofen API Market are

Speak to Analyst, Questions Related to Report @ https://www.futuremarketinsights.com/ask-question/rep-gb-11260

FMI Analyses the COVID-19 Impact on Market

FMI's analysis suggests that the ongoing COVID-19 pandemic is having adverse impacts on market growth. Wuhan, China is the hub of API supplies. The region is the epicentre of the coronavirus outbreak, as such, it has temporarily halted its manufacturing facilities.

Further, China is the prominent or the sole supplier of APIs including, penicillin and erythromycin, in the world. Manufacturers and distributors in the country are blaming logistical barriers and labour scarcity due to the COVID-19 pandemic for the delay in production and transportation.

Key Takeaways of Ibuprofen API Market Study

Lower labour cost and abundant availability of raw materials required for ibuprofen API are among the key factors fuelling the growth of the ibuprofen API market in South Asia. In addition, favourable regulatory support to establish ibuprofen API manufacturing businesses, and lower taxation policies are boosting the growth of the East and South Asia ibuprofen API market.

Buy Industry Research Report @ https://www.futuremarketinsights.com/checkout/11260 

Capacity Expansion, and Strategic Mergers & Acquisitions to Widen Regional Presence

Leading players in the ibuprofen API market ? SI Group, Inc., BASF SE, Hubei Biocause Pharmaceutical Co., Ltd. (BIOCAUSE Inc.), IOL Chemicals, Sino-US Zibo Xinhua-Perrigo Pharmaceutical Co., Ltd., and Solara Active Pharma Sciences Limited ? are focusing on business expansions by mergers, joint ventures, distribution agreements and capturing the untapped potential of the Ibuprofen API market.

Additionally, current acquisitions are focused on capacity expansion, and manufacturing capabilities of existing Ibuprofen API players to gain competitiveness and accelerate revenue growth in the market landscape.

Explore wide-ranging Coverage of FMI's Healthcare Market Insights Landscape

Anti-Asthma TDM Assay Kits Market ? The anti-asthma TDM assay kits market is anticipated to grow at a CAGR of 4.5% during the forecast period with a valuation of US$ 18 Bn in 2022.

Intranasal Corticosteroids Market ? The anti-asthma TDM assay kits market is anticipated to grow at a CAGR of 4.5% during the forecast period with a valuation of US$ 18 Bn in 2022.

Antinuclear Antibody Test Market ? The antinuclear antibody test market is likely to record a strong CAGR of 8% during the forecast period. The antinuclear antibody test market is currently valued at US$ 7.4 Bn in 2022 and is likely to reach US$ 17.25 Bn by 2032.

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of the Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favour the market growth in various segments based on Source, Application, Sales Channel and End-Use over the next 10-years.

Contact:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
For Sales Enquiries: [email protected] 
Website: https://www.futuremarketinsights.com 
Report: https://www.futuremarketinsights.com/reports/ibuprofen-api-market 
LinkedInTwitterBlogs

Logo: https://mma.prnewswire.com/media/1197648/FMI_Logo.jpg


These press releases may also interest you

at 06:15
The "Global Immune Health Supplements Market - Outlook & Forecast 2023-2028" report has been added to  ResearchAndMarkets.com's offering. The global immune health supplements market was valued at $20.80 billion in 2022 and is expected to reach...

at 05:45
The Gross Law Firm issues the following notice to shareholders of Amplitude, Inc. . Shareholders who purchased shares of AMPL during...

at 05:45
The Gross Law Firm issues the following notice to shareholders of Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II ....

at 05:30
The "Syndromic Multiplex Panels Markets. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) by Place, by Product and by Country. With Market Analysis and Executive Guides. 2024 to 2028" report has been added to...

at 05:00
The "Immunoassay Markets. Strategies and Trends. Forecasts by Application, Technology, Product, User and by Country. With Executive Guides, Customized Forecasting and Analysis. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering....

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...



News published on and distributed by: